APA (7th ed.) Citation

Rubbert-Roth, A., Kato, K., Haraoui, B., Rischmueller, M., Liu, Y., Khan, N., . . . Xavier, R. M. (2024). Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rheumatology & Therapy, 11(5), 1197. https://doi.org/10.1007/s40744-024-00694-x

Chicago Style (17th ed.) Citation

Rubbert-Roth, Andrea, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, and Ricardo M. Xavier. "Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study." Rheumatology & Therapy 11, no. 5 (2024): 1197. https://doi.org/10.1007/s40744-024-00694-x.

MLA (9th ed.) Citation

Rubbert-Roth, Andrea, et al. "Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study." Rheumatology & Therapy, vol. 11, no. 5, 2024, p. 1197, https://doi.org/10.1007/s40744-024-00694-x.